natgillin/translations-raw huggingface dataset:
Process according to any of claims 1 to 14, characterized in that the anion of said water-soluble salt is selected from the group consisting of phosphate, dihydrogen phosphate, monohydrogen phosphate, oxalate, silicate, mixtures thereof and hydrates thereof, more preferably from the group consisting of phosphate, dihydrogen phosphate, monohydrogen phosphate, mixtures thereof and hydrates thereof, and most preferably from the group consisting of dihydrogen phosphate, monohydrogen phosphate, mixtures thereof and hydrates thereof. 
Postupak prema bilo kojem od zahtjeva 1 do 14, naznačen time da je anion navedene kiseline topive u vodi odabran iz skupine koja sadrži fosfat, dihidrogen fosfat, monohidrogen fosfat, oksalat, silikat, njihove mješavine i njihove hidrate, poželjnije iz skupine koja sadrži fosfat, dihidrogen fosfat, monohidrogen fosfat, njihove mješavine i njihove hidrate, te najpoželjnije iz skupine koja sadrži dihidrogen fosfat, monohidrogen fosfat, njihove mješavine 1 njihove hidrate.
A hybridoma that produces the antibody of any of claims 1-9. 
Hibridoma koja stvara protutijelo iz bilo kojeg od patentnih zahtjeva 1-7.
A container according to any of claims 10 to 14, wherein the thickness of the lidding film is from 20 µm to 60 µm. 
Posuda prema bilo kojem od prethodnih Zahtjeva, gdje je debljina filma poklopca od 20 µm do 60 µm.
is selected from the group consisting of H and OH. 
Spoj izabran iz skupine koja se sastoji od:
In the most preferred embodiment the M3 antagonist of the invention and the corticosteroid are both present in the same pharmaceutical composition and are administered by inhalation through a common delivery device. 
U najpoželjnijem utjelovljenju, M3 antagonist sukladno predmetnom izumu I (32-agonist se nalaze u istom farmaceutskom pripravku i primjenjuju se inhalacijom putem zajedničke naprave za isporuku.
A composition of the invention is prepared by a method comprising admixing a Phenylene Compound or a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier or excipient. 
Sastav, naznačen time, da sadrži učinkovitu količinu spoja ili farmaceutski prihvatljive soli spoja prema patentnom zahtjevu 1 i farmaceutski prihvatljiv nosač ili ekscipijent.
n is 0, 1, 2, 3, or 4; and denotes a carbon-carbon single or double bond, wherein if Y is N, then R' is optionally substituted heterocyclic or optionally substituted carbocyclic, and comprises two or more fused rings, and wherein R' is not or wherein if Y is -C(R")-, then R' and R" taken together with the carbon atoms to which they are attached form an aryl or heteroaryl ring, each said ring is optionally substituted; 
j = 0; k = 0; m = 1; n je 0, 1, 2, 3, ili 4; i [image] predstavlja jednostruku ili dvostruku vezu ugljik-ugljik, Y je -C(R'')-, R' i R" uzeti zajedno s atomima ugljika na koje su vezani tvore arilni ili heteroarilni prsten, koji je po izboru supstituiran s jednom ili više R2;
is selected from hydrogen or F; and 
R5 je izabran od vodika ili F; i
irradiating a surface of the target with a laser or electron beam to generate a plume of target material particles; 
- < ozračivanje ciljne površine laserom ili elektronskom zrakom radi stvaranja fine prašine čestica ciljnog materijala;
Z-SO2-RV3 (Substituent group A, RV1, RV2, RV3, and Z are same meaning as those of claim 1). 
(Supstituentska skupina A, R"', R*, R*, i Z, imaju isto značenje kao što su navedeni u zahtjevu 1).
The disclosure also extends to cover, in all aspects described, the use of combinations of VZV antigens or derivatives with a live attenuated VZV strain or killed VZV. 
Upotreba u skladu s patentnim zahtjevom 1 ili 2, naznačena time što se VZV antigen gE unosi u pristupu s početnim stimulansom nakon živog oslabljenog VZV.
The explosion proof and environment protective gas refueling equipment of claim 5, wherein a plurality of explosion-proof material units are installed as filling material in the inner chamber of gas storage tank, and any two adjacent explosion-proof material units being interconnected. 
Oprema za nadolijevanje plina koja je otporna na eksploziju i štiti okoliš prema zahtjevu 5, naznačena time da je mnoštvo jedinica materijala (1) instalirano kao materijal ispune u unutrašnjoj komori spremnika za plin (A), te su bilo koje dvije susjedne jedinice materijala međusobno povezane.
-(C1-C6)-alkyl or -(C2-C6)-alkenyl, in which alkyl or alkenyl is unsubstituted or substituted independently of one another once, twice or three times by R1, 
-(C1-C6)-alkil ili -(C2-C6)-alkenil, gdje alkil ili alkenil nije supstituiran ili je međusobno neovisno mono-, di- ili trisupstituiran s R1,
For example, glycosyl-Y[—C(═Y)—X—]p-W(R)n-X—C(═Y)-drug where W is an aromatic or heteroaromatic or aliphatic group with conjugated double bonds or an amino-acid derivative radical which cyclizes after elimination of the glycosyl radical was disclosed in U.S. Pat. No. 6,146,658. 
Na primjer, glikozil-Y[-C(=Y)-X]p-W (R,)-X-C(=Y)-lijek gdje je W aromatska ili heteroaromatska ili alifatska grupa s konjugiranim dvostrukim vezama ili radikal aminokiselinskog derivata koji ciklizira nakon eliminacije glikozilnog radikala objavljen je u U.S. patentu br. 6 146 658.
The packaging blank according to claim 8, wherein said incision line at the periphery of said central area of said first area comprises an initiating portion arranged for facilitating initiation of the film. The packaging blank according to claim 8, wherein said incision line has a circular, oval, linear, circular arc, square shape with rounded apices, a rectangular shape with rounded apices, a hexagonal shape with rounded apices or further a finite curved line of irregular shape, allowing extraction from said container out of said partly detachable packaging section. 
Uzorak ambalažnog pakiranja u skladu s bilo kojim zahtjevima 12 do 14, naznačen time što navedena rezna linija ima oblik kruga, ovala, linije, luka kruga, kvadrata sa zaobljenim vrhovima, pravokutnika sa zaobljenim vrhovima, šesterokuta sa zaobljenim vrhovima ili čak zakrivljene završene linije nepravilnog oblika, omogućavajući vađenje navedenog spremnika van navedene djelomično odvojive sekcije (4) ambalažnog pakiranja.
The combination for use as claimed in any one of claims 1 to 5, wherein the ((2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate and the non-selective beta-adrenergic receptor blocker are administered topically as one or more eye drops to the eye of the subj etc. 
Kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 5, pri čemu se ((2R,3S,4R,5R)-5-(6-(ciklopentilamino)-9H-purin-9-il)-3,4-dihidroksitetrahidrofuran-2-il)metil nitrat i neselektivni blokator beta-adrenergičkog receptora primjenjuju topički kao jedna ili više kapi u oko subjekta.
In the most preferred embodiment the M3 antagonist of the invention and the PDE4 inhibitor are both present in the same pharmaceutical composition and are administered by inhalation through a common delivery device. 
U najpoželjnijem utjelovljenju, M3 antagonist sukladno predmetnom izumu i f2-agonist se nalaze u istom farmaceutskom pripravku i primjenjuju se inhalacijom putem zajedničke naprave za isporuku.
The composition for use according to any preceding claim, wherein the composition comprises a buffer which comprises citrate or sodium citrate, optionally 5mM to 50 mM sodium citrate, 10 mM to 30 mM sodium citrate, or 20 mM sodium citrate. 
Pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, naznačen time da pripravak sadrži pufer, koji sadrži citrat ili natrijev citrat, po potrebi 5SmM do 50 mM natrijevog citrata, 10 mM do 30 mM natrijevog citrata, ili 20 mM natrijevog citrata.
only one dose of netupitant is administered during said five days on day one, comprising about 300 mg of netupitant as the free base; and 
14. Farmaceutski pripravak prema patentnom zahtjevu 13, koji sadrži oko 300 mg netupitanta kao slobodnu bazu i oko 0.56 mg palonosetron hidroklorida.
A vector comprising the nucleic acid molecule of claim 7. A cell comprising the vector of claim 8. 
Vektor naznačen time da sadrži molekulu nukleinske kiseline prema zahtjevu 8.
The compound of Formula LXXII can be further hydrolysed to form a compound of Formula XX. 
HR P20121079 TI i i. >< deformaciju spoja Formule XIX, čime se dobiva spoj Formule XX:
A prokaryotic or eukaryotic host cell comprising the isolated nucleic acid molecule according to claim 8, wherein said host cell optionally is at least one selected from E. coli BL21Star(DE3), other E. coli cell, yeast, COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof. 
Prokariotska ili eukariotska domaćinska stanica koja sadrži izoliranu molekulu nukleinske kiseline prema patentnom zahtjevu 8, pri čemu je navedena domaćinska stanica opcionalno barem jedna izabrana od E. koli BL21Star (DE3), druga ćelija E. koli, kvasca, COS-1, COS- 7, HEK293, BHK21, CHO, BSC-I1, Hep G2, 653, SP2/0, 293, HeLa, mijeloma ili stanica limfoma, ili bilo koji njihovi derivati, besmrtne ili transformirane stanice.
Process according to claim 5, characterized in that a mix of fluids is used instead of monotype fluid, so as to reach a fluid mixture temperature which allows one or more fluids to maintain gas state behavior after the energy output in area (7) located inside the inner cylinder (3), while one or more other fluids are allowed to condensate thus improving the capacity of the fluid mixture to take advantage of phase change latent energy absorption and release to further counteract heating/cooling effects related to compression and decompression taking place in the installation in warmer and colder areas (5, 6). 
Proces opisan u patentnom zahtjevu 7, u okviru kojeg se umjesto jednog radnog fluida koristi mješavina više fluida, pri čemu je temperatura mješavine fluida takva da nakon odvođenja energije proizvedene u području (7), koje se nalazi unutar unutarnjeg cilindra (3), jedan ili više fluida iz mješavine ostaju u plinskom stanju, dok se jedan ili više fluida iz mješavine kondenzira, čime se omogućava da radna mješavina fluida bolje iskoristi latentnu toplinu oslobođenu tijekom promjene faze pojedinih fluida iz mješavine, a sve u cilju dodatnog smanjenja negativnih efekata zagrijavanja/hlađenja fluida pri povećanju i smanjenju pritiska u toplijim i hladnijim zonama (5, 6) sistema.
indication of the type of payment request, 
Broj objave europskog patenta:
A system as claimed in claim 5, wherein the surfaces are in the form of two plates or discs provided with a central bore arranged to allow the core of the cable to pass therethrough. 
Sistem kao što se zahtijeva u bilo kojem zahtjevu 5 do 7, naznačen time, da su površine u obliku dviju ploča ili diskova (41,42,43,44) pripremljenih s centralnim otvorom raspoređenim za dopuštanje jezgre (62) kabela (3) za prolaz kroz isti.
The compound of claim 3, wherein the compound is represented by the following structural formula: 
Spoj sukladno zahtjevu 1, naznačen time, da je spoj predstavljen slijedećom strukturnom formulom: raki
X is a carboxylic acid or a derivative thereof, such as, a carboxylic ester, a carboxylic anhydride, carboxamide, phospholipid, monoglyceride, diglyceride, or triglyceride; 
X je karboksilna kiselina ili njen derivat pri čemu je derivat karboksilni ester, karboksamid, monoglicerid, diglicerid, triglicerid ili fosfolipid; ili njegova farmaceutski prihvatljiva sol.
A pharmaceutically acceptable liquid composition comprising: active components comprising: 
Farmaceutski prihvatljiv tekući sastav iz zahtjeva 1 ili 2, sadržeći:
A composition comprising at least one isolated IL-6 antibody according to any of claims 1-5 and at least one pharmaceutically acceptable carrier or diluent, optionally further comprising at least one compound or polypeptide selected from a detectable label or reporter, a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an ophthalmic, otic or nasal drug, a topical drug, a nutritional drug, a cytokine, and a cytokine antagonist. 
Pripravak koji sadrži najmanje jedno izolirano anti IL-6 protutijelo prema bilo kojem od zahtjeva 1-3 i najmanje jedan farmaceutski prihvatljiv nosač ili otapalo, proizvoljno dalje sadrži najmanje jedan spoj ili polipeptid koji se bira od detektibilnog obilježivača ili reportera, antigonista TNF, protu-infektivnog lijeka, lijeka za kardiovaskularni sustav (CV), lijeka za središnji živčani sustav (CNS), lijeka za autonomni živčani sustav (ANS), lijeka za respiratorni trakt, lijeka za gastrointestinalni trakt (GI), hormonskog lijeka, lijeka za ravnotežu tekućina ili elektrolita, hematološkog lijeka, antineoplastika, imunomodulacijskog lijeka, očni, ušni ili nazalni lijek, topikalni lijek, prehrambeni lijek, citokin, te antagonist citokina.
cooling the clear solution to about 30°C while stirring under nitrogen atmosphere; 
(e) hlađenje bistre otopine na oko 30*C dok se ona miješa pod dušikovim zračnim omotačem;
An isolated antibody according to claim 1 for use in treating hematological cancer, wherein said hematological cancer is selected from the group consisting of multiple myeloma, chronic lymphoblastic leukemia, chronic lymphocytic leukemia, plasma cell leukemia, acute myeloid leukemia, chronic myeloid leukemia, B-cell lymphoma, and Burkitt's lymphoma. 
Izolirano protutijelo za uporabu u liječenju raka prema zahtjevu 9 naznačeno time da navedeni rak je hematološki rak i odabran je iz skupine koju čine multipli mijelom, kronična limfoblastična leukemija, kronična limfocitna leukemija, leukemija stanica plazme, akutna mijeloidna leukemija, kronična mijeloidna leukemija, limfom B stanica, i Burkittov limfom.
As illustrative but nonlimiting examples of terpenes indicated in b5), examples that may be mentioned include terpinenes, myrcene, limonene, terpinolene, pinenes, sabinene, camphene, and the like, mixtures of two or more thereof, and also terpene-based essences, especially those comprising these ingredients. 
12. Pripravak prema zahtjevu 7, gdje se b5) odabire između terpinena, mircena, limonena, terpinolena, pinena, sabinena, kamfena, smjesa dvaju ili više njih, i također esencija na bazi terpena, posebno onih koje sadrže te sastojke.
The method of claim 1, further comprising vaccinating the patient with the antigen. The method of claim 9, wherein the patient is vaccinated before the isolation of the cell. The method of claim 10, wherein the patient is vaccinated at least two days and/or at most eight weeks before isolation of the cell. 
Farmaceutski pripravak ili izolirane stanice za uporabu u skladu s jednim od zahtjeva 7 do 13, naznačen/e time, da se pacijent inokulirao s antigenom, poželjno prije izoliranja stanica, posebno poželjno prije perioda od najmanje dva dana i/ili najviše osam tjedana prije izoliranja stanica.
is 5 to 8 amino acid residues in length; 
je duljine 5 do 8 ostataka amino kiseline;
wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer; and wherein said oxime linkage formation is catalyzed by m-toluidine. 
pri čemu je vezanje oksima formirano između oksidiranog dijela karbohidrata i aktivne aminooksi skupine na polimeru topljivom u vodi; i pri čemu je spomenuto formiranje vezanja oksima katalizirano nukleofilnim katalistom m-toluidinom.
An isolated nucleic acid molecule encoding the antibody of claim 1 or the antigen binding fragment of claim 4 . 
Izolirana molekula nukleinske kiseline, naznačena time, što kodira antitijelo ili njegov antigen-vežući fragment iz zahtjeva 1.
The amount of IL-18BP was measured by determination of the optical density (OD) at 280 nm (molar extinction coefficient e=1.26) in the purified preparation of IL-18BP, i.e. after the final purification step by Reverse Phase chromatography. 
Količina IL-1$BP bila je izmjerena određivanjem optičke gustoće (OD) kod 280 nm (koeficijent molarne ekstinkcije e= 1.26) u pročišćenoj preparaciji IL-18BP primjerice nakon konačnog koraka pročišćavanja s pomoću kromatografije obrnute faze.
The soft capsule according to claim 7, wherein said plastifier is selected from the group consisting of polyhydroxy alcohols, 1,2-propylene glycol and sorbitol solutions. 
Meka kapsula u skladu s patentnim zahtjevom 5, naznačena time, da je navedeni plastifikator odabran iz skupine koja se sastoji od otopina polihidroksi alkohola, glicerola, 1,2-propilen glikola i sorbitola.
Further, it has also been found beneficial to adjust the water content of the granulate to 0.5 to 2.5 %, preferably 1.0 to 2.0 % by weight (determined as loss on drying, at 85°C, 20 minutes, e.g. with a Mettler Toledo HR73 halogen moisture analyser). 
Nadalje, također je utvrdeno povoljno djelovanje prilagodavanja sadržaja vode u granulatu na 0,5 do 2,5 %, poželjno 1,0 do 2,0 % masenog udjela (određeno kao gubitak tijekom sušenja, na 85?C, tijekom 20 minuta, na primjer sa Mettler Toledo HR73 halogenim analizatorom vlage).
Subject matter of this invention is therapeutic cocktails for the treatment of cancer diseases (including prostate cancer) one of the components of which is the new medicinal product or new pharmaceutical composition comprising at least one compound expressed by the general formula 1 as an active ingredient. 
u dimetilformamidu. Spoj koje je prikazano formulom 1 prema patentnom zahtjevu 1 koje ima svojstva antagoniste androgenih receptora, kao aktivni sastojak za proizvodnju medicinskog proizvoda za liječenje kancerogene bolesti.
An example of the resin base is described in the following. 
Primjer baze za smolu je kako je dalje opisano.
The composition according to any one of claims 1 to 7 comprising optionally at least one chelating agent. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što može sadržavati najmanje jedno kelirajuće sredstvo.
This may be done by removing the metal from an area such that the remaining metal is so thin that it is possible for the fields/signals to pass through the metal surface. 
To se može načiniti uklanjanjem metala iz područja, tako da je preostali metal tako tanak da je moguće za polja/signale da prođu kroz metalnu površinu.
Further provided is a package comprising (b) an M3 antagonist of the invention and (a) a PDE4 inhibitor for the simultaneous, concurrent, separate or sequential use in the treatment of a said respiratory disease. 
Također je omogućena proizvodnja paketa koji sadrži (b) M3 antagonist sukladno predmetnom izumu i (a) kortikosteroid za istovremenu, paralelnu, odvojenu ili seckvencijalnu uporabu u liječenju navedenih respiratornih bolcsti.
It is highly preferred to use trimethylaminoethyl-derivatized resin, such as TMAE Fractogel® (or TMAE HiCap®) as ion exchange material. 
Još je poželjnije da se koristi nosač derivatiziran s trimetilaminoetilom poput TMAE Fractogel" (ili TMAE HiCap") kao materijal za ionsku izmjenu.
preparing amorphous solid clopidogrel hydrogen sulfate, and 
dobivanja amorfnog klopidogrel-hidrogensulfata, te
A method according to claim 8, characterised in that the adjusted dose is the one, among the first and second doses, for which the absolute value of the variable B is lower. 
Metoda sukladno zaštiti 8, naznačena time što je prilagođena doza između prve i druge doze ta čija je apsolutna vrijednost varijable B niža.
A method for separating wax from a dried wax coated plant material, comprising the steps of: mechanically processing the plant material in a dry process by using an apparatus adapted for deforming at least the outer surface of the plant material, so that the wax coating is cracked and released from the remaining, partly de-waxed, plant material, 
Postupak za izdvajanje voska iz biljnog materijala obloženog suhim voskom, naznačen time što se sastoji u koracima: a. = mehaničke obrade biljnog materijala u suhom postupku uređajem podešenim za deformiranje u najmanju ruku vanjske površine biljnog materijala, tako da voštana obloga ispuca i odvoji se od preostalog, djelomično odvoštenog, biljnog materijala, b. - transporta biljnog materijala u cijevi nepropusnoj za prašinu za odsisavanje, c.
The invention provides a colon cleansing solution comprising: a) 300 to 2000 mmol per liter ascorbate anion provided by ascorbic acid, one or more salts of ascorbic acid, or a mixture thereof; and b) 10 to 200 g per liter polyethylene glycol. 
Otopina za čišćenje debelog crijeva naznačena time da sadrži: a) 300 do 2000 mmol po litri askorbatnog aniona osiguranog putem askorbinske kiseline, jedne ili više soli askorbinske kiseline, ili njihove smjese; i b) 10 do 200 g po litri polietilen glikola.
The bispecific IgG antibody according to claim 18, wherein said mutated CH2 and/or lower hinge domains comprise amino acid substitution L235G and/or G236R. 
Bispecifično IgG protutijelo sukladno patentnom zahtjevu 6 ili 7, naznačeno time što navedeni mutirani CH2 i/ili niže zglobne domene sadrže supstituciju L235G i/ili G236R, poželjno L235G i G236R.
Ingested surfactants may facilitate penetration or absorption of potentially toxic or pathogenic compounds, which in turn may result in adverse effects on the other organs (Lieberman, H. A., Rieger, M. M. and Banker, G. S., Eds., Pharmaceutical. 
Progutani surfaktanti mogu olakšati unos ili apsorpciju potencijalno toksičnih ili patpgenih spojeva, koji naizmjence mogu rezultirati u suprotnom učinku na ostale organe (Lieberman, H.A., Rieger, M.M.
is selected from hydrogen, CORa, COORa, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, and substituted or unsubstituted C4-C12 alkenynyl; is selected from hydrogen, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; 
Ra se bira između vodika, COR,, COOR, supstituiranog ili nesupstituiranog C;-C,> alkila, supstituiranog ili nesupstituiranog C2-Cpx_ alkenila, supstituiranog ili nesupstituiranog C2-Ci2_ alkinila, 1 supstituiranog ili nesupstituiranog C4-C;2 alkeninila; Rio se bira između vodika, supstituiranog ili nesupstituiranog C;-C;> alkila, supstituiranog
Since treatment with the selective NE reuptake inhibitor reboxetine has been shown to stimulate 5-HT neurons and mediate the release of 5-HT in the brain (Svensson, T. et al, J. Neural. 
Od kad je započeto s liječenjem selektivnom NE inhibicijopm re-apsorpcije ustanovljeno je da inhibitor reboxetine stimulira 5-HT neurone i posreduje kod oslobađanja 5-HT u mozgu.(Svenson, T. et al, J. Neural.
building a signal frame comprising one or more data slices carrying PLP and one or more preamble symbols carrying Layer 1, L1, signaling data for the data slices, wherein the preamble symbols are divided in frequency direction into at least two L1 blocks of same bandwidth, and the signal frame comprises a Layer 2, L2, information including a network information table, NIT, having an identifier of a physical layer pipe (PLP_id) and an identifier of a transmission system (transmission_system_id) corresponding to the transport stream in the signal frame; 
dodjeljivanje (S1703) simbola za podatkovni komad okviru signala i organiziranje informacija sloja 1 i sloja 2 u okviru signala, informacija sloja 1 obuhvaća identifikator podatkovnog komada za podatkovni komad i identifikator PLP-a za PLP, informacija sloja 2 obuhvaća NIT čiji deskriptor odgovara prijenosnom toku u signalu okvira, gdje deskriptor obuhvaća identifikator PLP-a, identifikator sustava prijenosa, informaciju za tuniranje frekvencije prijenosnog sustava, aktivno polje trajanja OFDM simbola i polje zaštitnog intervala;
An antibody or immunological functional fragment thereof that induces FGF21-mediated signaling, and specifically binds to at least one of: 
Izolirano antitijelo ili njegov fragment koje je sposobno za vezanje za kompleks koji sadrži B-Klotho i FGFR1c i inducira FGF21-posredovani prijenos signala i sadrži sljedeće CDR regije: